Size | Price | Stock | Qty |
---|---|---|---|
100mg |
|
||
250mg |
|
||
500mg |
|
||
1g |
|
||
Other Sizes |
|
Biperiden HCl (trade name Akineton; Akinophyl), the hydrochloride salt of Biperiden, is a potent muscarinic antagonist and a medication used to treat Parkinson disease and certain drug-induced movement disorders. For tardive dyskinesias, it is not advised. It is injected into a vein, muscle, or taken orally.
ln Vitro |
Biperiden hydrochloride (29.6 μg/ml, 72 hours) can dramatically suppress proliferation and cause apoptosis in human pancreatic ductal adenocarcinoma cells when applied at high concentrations[1].
|
---|---|
ln Vivo |
Biperiden hydrochloride (intraperitoneal injection, 10 mg/kg, everyday, 3 weeks) reduces tumor size by 83% in subcutaneous xenograft mice using Panc-1 human pancreatic ductal adenocarcinoma cells[1].
Biperiden hydrochloride (intraperitoneal injection, 8 mg/kg, every 8 hours, 10 days) can lower extracellular hippocampal glutamate levels and the frequency of spontaneous seizures while permanently lowering hippocampal excitability[2]. |
Cell Assay |
Cell Line: Panc-1, Panc-2 and BxPC3 human pancreatic ductal adenocarcinoma cells
Concentration: 29.6 μg/mL Incubation Time: 72 hours Result: Inhibited cell proliferation at 72 hours significantly by reducing nuclear c-Rel translocation. |
Animal Protocol |
Subcutaneous xenograft mouse using Panc-1 human pancreatic ductal adenocarcinoma cells[1]
10 mg/kg Intraperitoneal injection; everyday; 3 weeks |
References |
|
Molecular Formula |
C21H30CLNO
|
---|---|
Molecular Weight |
347.92
|
Exact Mass |
347.2
|
Elemental Analysis |
C, 72.49; H, 8.69; Cl, 10.19; N, 4.03; O, 4.60
|
CAS # |
1235-82-1
|
Related CAS # |
Biperiden; 514-65-8; Biperiden lactate; 7085-45-2; Biperiden-d5 hydrochloride; rel-Biperiden-d5; rel-Biperiden EP impurity A-d5; rel-Biperiden EP impurity B-d5
|
Appearance |
White to off-white solid powder
|
SMILES |
C1CCN(CC1)CCC(C2CC3CC2C=C3)(C4=CC=CC=C4)O.Cl
|
InChi Key |
RDNLAULGBSQZMP-UHFFFAOYSA-N
|
InChi Code |
InChI=1S/C21H29NO.ClH/c23-21(19-7-3-1-4-8-19,11-14-22-12-5-2-6-13-22)20-16-17-9-10-18(20)15-17;/h1,3-4,7-10,17-18,20,23H,2,5-6,11-16H2;1H
|
Chemical Name |
1-(2-bicyclo[2.2.1]hept-5-enyl)-1-phenyl-3-piperidin-1-ylpropan-1-ol;hydrochloride
|
Synonyms |
Akineton hydrochloride; Akineton; Akinophyl; Biperiden Hydrochloride; Biperiden; Biperiden
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO: ~20 mg/mL (~57.5 mM)
H2O: ~5 mg/mL (~14.4 mM) |
---|---|
Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.8742 mL | 14.3711 mL | 28.7422 mL | |
5 mM | 0.5748 mL | 2.8742 mL | 5.7484 mL | |
10 mM | 0.2874 mL | 1.4371 mL | 2.8742 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT04945213 | Recruiting | Drug: Biperiden Other: Placebo |
Post Traumatic Epilepsy Brain Injury Traumatic Severe |
Hospital Sirio-Libanes | January 10, 2023 | Phase 3 |
Biperiden (Bip) and mepazine (Mep) are able to bind in the allosteric MALT1 binding pocket and can reduce the MALT1 activity of dimeric recombinant hMALT1 (339–719) protein. Int J Cancer . 2020 Mar 15;146(6):1618-1630. td> |
MALT1 is expressed and highly active in human pancreatic cancer cells; MALT1 inhibition by biperiden (Bip) or mepazine (Mep) elicit toxic effects. Int J Cancer . 2020 Mar 15;146(6):1618-1630. td> |